Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions View by Topic View by Date Must Reads by Date Must reads for theWeek ending December 29, 2019 Dual HER2 therapy added to CRT for esophageal cancer is tolerable, active, Data support maintenance in metastatic colorectal cancer, ctDNA shows clinical value in advanced breast cancer, Urothelial cancer: Less gained from immunotherapy in patients with poor performance scores, Standard-dose RT with concurrent chemo found superior for unresectable NSCLC, More must reads Must reads for theWeek ending December 22, 2019 LOXO-305: Next-Gen BTK Inhibitor Safe and Effective in B-Cell Malignancies, Survival Data Reported From Largest CAR T Trial in B-Cell Lymphoma, Sensitivity of ctDNA equivalent to that of tumor tissue sequencing, Neoadjuvant cisplatin fails to beat standard AC in HER2-negative breast cancer, Chemotherapy better for metastatic breast cancer maintenance than durvalumab, More must readsMust reads for theWeek ending December 8, 2019 Study IDs factors tied to improved survival in Burkitt lymphoma, Clinical Model Helps Predict Outcomes in R/R DLBCL, Incidence of R/R DLBCL Lower Than Expected in Population-Based Study, Fragmentation of sickle cell disease care starts in young adulthood, Care Coordination, Equity Can Eliminate Disparities for Nonwhite Patients with DLBCL, More must readsMust reads for theWeek ending December 8, 2019 Study IDs factors tied to improved survival in Burkitt lymphoma, Clinical Model Helps Predict Outcomes in R/R DLBCL, Incidence of R/R DLBCL Lower Than Expected in Population-Based Study, Fragmentation of sickle cell disease care starts in young adulthood, Care Coordination, Equity Can Eliminate Disparities for Nonwhite Patients with DLBCL, More must readsMust reads for theWeek ending December 1, 2019 Combo Elicits Lasting Responses in Metastatic Melanoma, Atezolizumab/bevacizumab may offer benefit to patients with RCC, Adding Polatuzumab Extends Survival in Relapsed/Refractory DLBCL, Survey: Cancer-Related Pain, Opioid Use Up Since 2018, Use of Salvage Plus ASCT in DLBCL With End-Stage Renal Disease, More must readsPages« first 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 last »